Ruti Aga's Six-Year Ban: The Prescription Was Forged, the Clinic Never Existed — and the Drug Wasn't What Was Reported

The stamp was on the prescription. The clinic had an address. The drug had a name. When the Athletics Integrity Unit (AIU) went looking for the clinic, it did not exist. The person who wrote the prescription had no medical registration — he was a member of Ruti Aga's family. Asked where the prescription came from, he said an old pad from a former workplace. The clinic whose name was printed on that pad said it had nothing to do with it. Three verifications, three failures. There is no race time in this story. Aga won a half marathon in China in March, but the report carries no mark, no split, no field strength. What it carries is paper. And in a paper story, the first job is to read what the paper says and what it hides. A technical error has already been made: most reports called methylprednisolone a “prohibited steroid”. That is wrong. It is a glucocorticoid — class S9 of the WADA Prohibited List — and it is prohibited in-competition only, by injection, oral or rectal route. The entire case turns on route and timing, not on “steroid use”. I watched the 2026 Tokyo Marathon at four in the morning in my drawing room in Ahmedabad. Aga won it, and the only line in my notebook that morning was this: Ethiopia's depth is such that its fourth or fifth runner would be another country's star. Aga sat at the top of that depth — a Tokyo title and three second places at World Marathon Majors. My old ledger has 2:18:34 from Berlin 2026 written in it, but I did not re-check that against an official result for this report, so I keep it inside the boundary of recall. Aga is 32 now, and she has a six-year ban. The AIU statement issued on Thursday makes clear the suspension runs from 10 September, which is the date of her provisional suspension. The six years are built in two parts: two years for the presence violation, four years for tampering and for misleading the investigation with a fabricated document. Two plus four is six. That arithmetic is worth reading, because the whole verdict is inside it. Methylprednisolone is the most common knee injection in sport. Distance runners with knee synovitis are treated with it routinely, and out of competition that treatment is entirely legal. The rule says an S9 substance is prohibited only in-competition; treatment outside is fine, provided no residue is present when the athlete competes. On the road, the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. The question is not whether she took the drug. The question is when it went in and how long it stayed. That is why the knee-injury explanation is technically credible — and why it was legally fatal. Marathoners' knees wear out; at 32, running 180 to 200 kilometres a week, knee pain is not an excuse, it is the daily truth. Before the medal there is a body keeping a secret. But when the treatment is real, it is defended with real records: clinic notes, a doctor's registration, the injection date, and where needed an application for a Therapeutic Use Exemption. Aga had none of these. The knee problem was probably not a March problem but a years-long one. An athlete who has a document manufactured is often not doing it for the first time; she is at the end of a habit that grew because no formal treatment pathway was ever built. That is inference, not proof, and I will label it as inference. Here is a human truth I have kept in my ledger since 2026: the number was 6.83. The story was a kidney nobody mentioned. A performance never arrives alone — behind it sit the job, the funding, the camp, the coach's airfare and the medical arrangement. In Aga's case the medical arrangement was not formal at all. The “doctor” was a relative, the clinic did not exist, and the prescription came off a pad the clinic itself disowned. Three checks, three answers, and one thing missing from all of them — an institution. This was not a filing error; it was the signature of an athlete operating without a credentialed team physician. Across East African road running that picture is familiar: an agent, a coach, training partners, and a medical network that runs on phone calls rather than records. When injury arrives, the cheapest and most available tool is a glucocorticoid injection, and manufacturing the paper for it is the easiest task in the room. Back to the arithmetic. Two years for the substance, four for the tampering. The two-year part tells us the panel did not find proven intent — this is a Specified Substance case, and such cases can be reduced where intent is absent. The four-year part tells us the panel granted no no-significant-fault mitigation. The document that was meant to be the defence became the thing that removed the defence. Two plus four is not a schedule; it is a sentence: the drug error cost two years, the paper error cost four. Backdating to 10 September is not a discount. Time served under provisional suspension counts against the ban; the athlete gains nothing real. What the statement does not spell out is the scope of disqualification. AIU practice is to annul the result and prize money from the competition where the sample was collected — meaning the March half marathon in China, its title and its appearance money, are all in jeopardy, along with ranking points accrued after that date. The 2026 Tokyo title does not fall automatically, because the violation is anchored to a later race and no finding of earlier use appears in the source. That distinction matters: one title goes, one record stays. Six years from 32 means she next races at 38. In Ethiopian women's marathon depth, even a 2:18 performer is not automatically selectable. A 38-year-old returnee with a doping record is selectable on paper only. Read that way, this is not a six-year ban; it is the end of a career — and the drug did not end it. The paper did. I keep an archive of everything nobody said on air. In that archive, Aga's name now goes on two shelves. One holds the Tokyo title and three Major second places — it is true that she was an elite marathoner. The other holds a prescription that belonged to no clinic. Sponsorship in distance running is thin to begin with; after a doping record it gets thinner. That split is the real accounting of her legacy. Since 2026 I have written a mandatory paragraph into every medal report: who employs the athlete, who tests her, and who signs off on what she swallows. That habit cost me two sponsors and one anchor chair. Writing it for Aga returns blanks: no employer named, the test is the AIU's, and the signature on the swallowed substance belongs to a man who was never a doctor. Here is the part least written. This is not one athlete's file. The tampering charge in the AIU investigation came out of an interview, not out of a document alone. Language and translation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention. That does not weaken the charge, but it is a reminder that the interview room is built from the same inequality the athlete comes out of. And the agent or management that accepted or suggested the document is not named in the AIU statement. Only the family member is. There is an economic layer almost nobody connects. China's label races are the easiest income tier for East African marathoners between Majors — large appearance fees, few races, low risk. Those same races are now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding on the same track. And where the entourage has no medical paperwork, tampering cases will cluster — not coincidence, structure. This is where my contrarian reading begins. The six years are not for a drug with no proven endurance benefit. They are for the paper that was asking for help. Calling this a steroid case is convenient, because it lets the file stand in a queue of anabolic-steroid cases where comparison is easy and the severity looks self-evident. The comparison is wrong. An S9 case is a case about treatment, route and timing. Calling it a steroid case buries a mistake the athlete made and the system allowed. The harder truth is that Aga destroyed the only defence that could have worked. With genuine treatment records and a clean injection date, the two-year presence sanction could have been argued down — perhaps to a reprimand. The four-year tampering term would never have existed. In the best case, correct timing and correct route would have meant no case at all. This argument is not here to rescue her; it is here to name the error that cost more than the defence. I close the file. In my ledger the heading for this case reads: there was no treatment arrangement, so a document was made. The drug did not end the career. The paper did. And the system that let a 32-year-old run without a credentialed doctor is the same system now removing her for six years. Both statements sit in the same file, and both are true. What to watch next. The CAS appeal window is typically about 21 days from the reasoned decision, and on a document-based finding an appeal has limited value. What matters more is whether the AIU reaches the agent or the entourage, and whether the Ethiopian federation builds a formal medical support structure for its runners. Until it does, the next 32-year-old with a sore knee will look again at the same old prescription pad. The question is not whether the sanction was harsh or soft; it is who she will be able to call next time.